

ASX Announcement

Results of Annual General Meeting

Sydney, Australia, 13 November 2025: Imugene Limited (ASX:IMU) (Imugene, or the Company) is pleased to announce the results of today's Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporation's Act.

The Company advises that 30.55% of the votes cast on Resolution 1 were against the adoption of the Remuneration Report which constitutes a 'second strike' for the purposes of the Corporations Act 2001 (Cth).

Resolution 10 – Spill Resolution was then put to the meeting and was not passed with 84.06% of the votes cast against the Spill Resolution.

Release approved by the Company Secretary on behalf of the Board.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

General Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited
Follow us on Twitter @TeamImugene
Watch us on YouTube @ImugeneLimited



About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies may become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Disclosure of Proxy Votes

Imugene Limited

Annual General Meeting

Thursday, 13 November 2025



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Remuneration Report	P	65,990,893	45,518,498 68.98%	20,161,315 30.55%	402,439	311,080 0.47%	47,257,888 69.67%	20,568,896 30.33%	402,439	-
2 Re-election of Director – Mr Paul Hopper	P	76,885,678	57,018,072 74.16%	19,581,536 25.47%	478,601	286,070 0.37%	59,033,537 74.99%	19,688,032 25.01%	478,601	Carried
3 Re-election of Director – Dr Jakob Dupont	P	75,864,677	69,647,831 91.81%	5,792,166 7.63%	1,499,602	424,680 0.56%	72,060,499 92.74%	5,640,069 7.26%	1,499,602	Carried
4 Issue of performance rights to Director – Mr Paul Hopper	P	68,606,367	46,275,300 67.45%	22,158,192 32.30%	981,220	172,875 0.25%	47,876,485 67.97%	22,565,773 32.03%	981,220	Carried
5 Issue of performance rights to Director – Ms Leslie Chong	P	73,726,856	60,341,487 81.84%	13,082,997 17.75%	804,118	302,372 0.41%	62,308,522 82.46%	13,254,225 17.54%	804,118	Carried
6 Issue of restricted stock units to Director – Dr Jakob Dupont	P	74,915,100	62,113,892 82.91%	12,372,682 16.52%	2,431,847	428,526 0.57%	64,236,194 83.69%	12,514,797 16.31%	2,431,847	Carried
7 Issue of restricted stock units to Director – Dr Lesley Russell	P	75,357,138	61,641,766 81.80%	13,284,783 17.63%	1,992,435	430,589 0.57%	63,766,131 82.61%	13,426,898 17.39%	1,992,435	Carried
8 Issue of restricted stock units to Director – Ms Kim Drapkin	P	75,355,254	61,659,367 81.82%	13,266,206 17.60%	1,990,817	429,681 0.57%	63,782,824 82.63%	13,408,321 17.37%	1,990,817	Carried



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Approval of 10% capacity under Listing Rule 7.1A	P	75,651,936	67,539,081 89.28%	7,723,555 10.21%	1,711,991	389,300 0.51%	69,593,044 89.85%	7,865,371 10.15%	1,741,403	Carried
10 Contingent business - Board Spill Meeting (conditional item) If less than 25% of the votes cast on Resolution 1 are voted against adoption of the Remuneration Report, the Chair will withdraw Resolution 10. IMPORTANT - The Board strongly recommends you vote against Resolution 10.	P	76,845,297	11,853,989 15.43%	64,596,539 84.06%	518,613	394,769 0.51%	11,837,472 15.05%	66,833,421 84.95%	528,908	Not Carried

